drugset / Trial / NCT01281592
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, phase 1 study to determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.
Timeline
- Start
- 2011-01
- Primary completion
- 2013-07
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APTO-253 | Small molecule | 20 mg/m2 | — |
Indications
No indication recorded.